ClinicalTrials.gg
CompletedNCT02217904Updated Aug 12, 2019Results posted

A Study of Islatravir (MK-8591) in Anti-Retroviral Therapy-Naive, Human Immunodeficiency Virus-1 Infected Participants (MK-8591-003)

A Phase 1 interventional study of 1 mg islatravir and 2 mg islatravir in HIV-1, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2019-08-12.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

This study will evaluate the safety, tolerability, pharmacokinetics, and anti-retroviral therapy (ART) activity of islatravir (MK-8591) monotherapy in ART-naive, human immunodeficiency virus-1 (HIV-1) infected participants. The primary hypothesis is that at a safe and tolerable dose of islatravir, the true mean difference in the plasma HIV-1 ribonucleic acid (RNA) reduction from baseline between islatravir and placebo is at least 0.5 log (base10) copies/mL.

02

Conditions studied

  • HIV-1
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Non-pregnant, non-breast feeding, or surgically sterile female
  • Female with agrees to use (or have male partner use) two acceptable methods of
  • Male agrees to use acceptable method of contraception during study and for 90 days after last dose of trial drug
  • Has stable baseline health, other than infection
  • Has no significantly abnormal
  • Is HIV-1 positive
  • Have a screening plasma HIV-1 RNA ≥ 10,000 copies/mL within 30 days prior to the treatment phase of this study. For inclusion in Panel Islatravir Extended Observation, participants must also have a screening plasma HIV-1 RNA ≤ 25,000 copies/mL within 30 days prior to the treatment phase.
  • Is ART naive
  • Has not received any agent or marketed ART within 30 days of trial drug administration
  • Is diagnosed with HIV-1 infection >= 3 months prior to screening
  • Is willing to receive no other ART during treatment phase of study
  • Has no evidence of mutations conferring resistance to nucleoside reverse transcriptase inhibitors (NRTIs)

Exclusion criteria

Exclusion Criteria:

  • Is mentally or legally institutionalized/incapacitated, or has significant emotional problems, or has a history of psychiatric disorder of the last 5 years
  • Has a history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological (outside of -1 infection), renal, respiratory, genitourinary, major neurological abnormalities or diseases
  • Has a history of cancer ()
  • Has a history of significant multiple and/or severe allergies, or had an anaphylactic reaction to drugs or food
  • Is positive for surface antigen
  • Has a history of chronic
  • Had major surgery or lost 500 mL of blood with 4 weeks prior to screening visit
  • Has participated in another trial within 4 weeks prior to dosing visit
  • Will use any medications, prescribed drugs, or herbal remedies 4 weeks prior to dosing of trial drug, up to the post-trial visit
  • Consumes excessive amounts of alcohol, caffeinated beverages, or tobacco products
  • Uses illicit drugs or has a history of drug abuse within the prior 2 years
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Islatravir 1 mg

    Single oral dose of islatravir 1 mg

    Drug: 1 mg islatravir

  • Experimental
    Islatravir 2 mg

    Single oral dose of islatravir 2 mg

    Drug: 2 mg islatravir

  • Experimental
    Islatravir 10 mg

    Single oral dose of islatravir 10 mg

    Drug: 10 mg islatravir

  • Experimental
    Islatravir 30 mg

    Single oral dose of islatravir 30 mg

    Drug: 30 mg islatravir

  • Experimental
    Islatravir 0.5 mg

    Single oral dose of islatravir 0.5 mg

    Drug: 0.5 mg islatravir

  • Experimental
    Islatravir 0.25 mg

    Single oral dose of islatravir 0.25 mg

    Drug: 0.25 mg islatravir

  • Experimental
    Islatravir 30 mg Extended Observation

    Single oral dose of 30 mg islatravir administered following \>8 hour fast. Participants will be closely monitored for viral load for up to approximately 21 days prior to starting standard of care ART.

    Drug: 30 mg islatravir

Interventions

  • Single oral dose of 1 mg islatravir administered following ≥8 hour fast

    Also known as: MK-8591

  • Single oral dose of 2 mg islatravir administered following ≥8 hour fast

    Also known as: MK-8591

  • Single oral dose of 10 mg islatravir administered following ≥8 hour fast

    Also known as: MK-8591

  • Single oral dose of 30 mg islatravir administered following ≥8 hour fast

    Also known as: MK-8591

  • Single oral dose of 0.5 mg islatravir administered following ≥8 hour fast

    Also known as: MK-8591

  • Single oral dose of 0.25 mg islatravir administered following ≥8 hour fast

    Also known as: MK-8591

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Plasma HIV-1 RNA at 168 Hours Post-Dose

    Plasma HIV-1 RNA was measured using the Roche COBAS Ampliprep/COBAS TaqMan HIV-1 test v.2.0, which has a linear range from 20 to 10,000,000 copies/mL. The lower limit of detection has 100% specificity at 20 copies/mL. Additionally, the test increases the probability of detection and expands coverage by targeting two highly conserved regions of the HIV-1 genome to compensate for the possibility of mutations or mismatches.

    Time frame: Baseline and 168 hours (7 days) post-dose

  2. Number of Participants With One or More Adverse Events

    An adverse event (AE) is any untoward medical occurrence in a study participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.

    Time frame: Up to 21 days post-dose

Secondary outcomes

  1. Area Under the Concentration-Time Curve of Islatravir Triphosphate in Peripheral Blood Mononuclear Cells From Time 0 to 168 Hours (AUC0-168hr)

    Blood was collected to measure intracellular islatravir triphosphate concentration in peripheral blood mononuclear cells and determine AUC0-168hr.

    Time frame: 4, 12, 24, 96, 120, 144, and 168 hours after islatravir administration. Value at predose was inferred from plasma predose sample.

  2. Maximum Concentration (Cmax) of Islatravir Triphosphate in Peripheral Blood Mononuclear Cells

    Blood was collected to measure intracellular islatravir triphosphate concentration in peripheral blood mononuclear cells and determine Cmax.

    Time frame: 4, 12, 24, 96, 120, 144, and 168 hours after islatravir administration. Value at predose was inferred from plasma predose sample.

  3. Concentration of Islatravir Triphosphate in Peripheral Blood Mononuclear Cells at 168 Hours Post-Dose (C168hr)

    Blood was collected to measure intracellular islatravir triphosphate concentration in peripheral blood mononuclear cells and determine C168hr.

    Time frame: 168 hours after islatravir administration

  4. Time to Maximum Concentration (Tmax) of Islatravir Triphosphate in Peripheral Blood Mononuclear Cells

    Blood was collected to measure intracellular islatravir triphosphate concentration in peripheral blood mononuclear cells and determine TMax.

    Time frame: 4, 12, 24, 96, 120, 144, and 168 hours after islatravir administration. Value at predose was inferred from plasma predose sample.

  5. Apparent Terminal Half-Life (t1/2) of Islatravir Triphosphate in Peripheral Blood Mononuclear Cells

    Blood was collected to measure intracellular islatravir triphosphate concentration in peripheral blood mononuclear cells and determine apparent terminal t1/2.

    Time frame: 4, 12, 24, 96, 120, 144, and 168 hours after islatravir administration. Value at predose was inferred from plasma predose sample.

  6. Area Under the Plasma Concentration-Time Curve of Islatravir From Time 0 to 168 Hours (AUC0-168hr)

    Blood was collected for the determination of AUC0-168hr of islatravir in plasma.

    Time frame: Predose and at 0.25, 0.5, 1, 2, 4, 8, 12, 24, 48, and 96 hours after islatravir administration. Value at 168 hours was extrapolated.

  7. Maximum Plasma Concentration (Cmax) of Islatravir

    Blood was collected for the determination of Cmax of islatravir in plasma.

    Time frame: Predose and at 0.25, 0.5, 1, 2, 4, 8, 12, 24, 48, and 96 hours after islatravir administration

  8. Time to Maximum Plasma Concentration (Tmax) of Islatravir

    Blood was collected for the determination of Tmax of islatravir in plasma.

    Time frame: Predose and at 0.25, 0.5, 1, 2, 4, 8, 12, 24, 48, and 96 hours after islatravir administration

  9. Apparent Terminal Half-Life (t1/2) of Islatravir in Plasma

    Blood was collected for the determination of apparent terminal t1/2 of islatravir in plasma.

    Time frame: Predose and at 0.25, 0.5, 1, 2, 4, 8, 12, 24, 48, and 96 hours after islatravir administration

07

Results

Posted Dec 3, 2018

Participant flow

Participant flow — Overall Study
MilestonePanel A: 10 mg IslatravirPanel B: 2 mg IslatravirPanel C: 30 mg IslatravirPanel D: 1 mg IslatravirPanel E: 0.5 mg IslatravirPanel F: 0.25 mg IslatravirPanel G: 30 mg Islatravir Extended Observation
Started6666600
Completed6666600
Not completed0000000

Outcome measures

PrimaryChange From Baseline in Plasma HIV-1 RNA at 168 Hours Post-Dose

Plasma HIV-1 RNA was measured using the Roche COBAS Ampliprep/COBAS TaqMan HIV-1 test v.2.0, which has a linear range from 20 to 10,000,000 copies/mL. The lower limit of detection has 100% specificity at 20 copies/mL. Additionally, the test increases the probability of detection and expands coverage by targeting two highly conserved regions of the HIV-1 genome to compensate for the possibility of mutations or mismatches.

Time frame:
Baseline and 168 hours (7 days) post-dose
Reported as:
Least squares mean · log10 copies/mL
Change From Baseline in Plasma HIV-1 RNA at 168 Hours Post-Dose
log10 copies/mLPanel A: 10 mg IslatravirPanel B: 2 mg IslatravirPanel C: 30 mg IslatravirPanel D: 1 mg IslatravirPanel E: 0.5 mg Islatravir
Change From Baseline in Plasma HIV-1 RNA at 168 Hours Post-Dose-1.67 (-1.92 to -1.42)-1.35 (-1.60 to -1.10)-1.60 (-1.85 to -1.34)-1.30 (-1.55 to -1.05)-1.20 (-1.46 to -0.95)
Statistical analysis
  • Panel A: 10 mg Islatravir · Posterior mean difference: -1.64Posterior Probability (PP) of true mean difference in the plasma HIV-1 RNA change from baseline between islatravir and placebo at least 0.5 log10 copies/mL was \>99%.
  • Panel B: 2 mg Islatravir · Posterior mean difference: -1.32Posterior Probability (PP) of true mean difference in the plasma HIV-1 RNA change from baseline between islatravir and placebo at least 0.5 log10 copies/mL was \>99%.
  • Panel C: 30 mg Islatravir · Posterior mean difference: -1.57Posterior Probability (PP) of true mean difference in the plasma HIV-1 RNA change from baseline between islatravir and placebo at least 0.5 log10 copies/mL was \>99%.
  • Panel D: 1 mg Islatravir · Posterior mean difference: -1.28Posterior Probability (PP) of true mean difference in the plasma HIV-1 RNA change from baseline between islatravir and placebo at least 0.5 log10 copies/mL was \>99%.
  • Panel E: 0.5 mg Islatravir · Posterior mean difference: -1.18Posterior Probability (PP) of true mean difference in the plasma HIV-1 RNA change from baseline between islatravir and placebo at least 0.5 log10 copies/mL was \>99%.
PrimaryNumber of Participants With One or More Adverse Events

An adverse event (AE) is any untoward medical occurrence in a study participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.

Time frame:
Up to 21 days post-dose
Reported as:
Count of participants · Participants
Number of Participants With One or More Adverse Events
ParticipantsPanel A: 10 mg IslatravirPanel B: 2 mg IslatravirPanel C: 30 mg IslatravirPanel D: 1 mg IslatravirPanel E: 0.5 mg Islatravir
Number of Participants With One or More Adverse Events55656
SecondaryArea Under the Concentration-Time Curve of Islatravir Triphosphate in Peripheral Blood Mononuclear Cells From Time 0 to 168 Hours (AUC0-168hr)

Blood was collected to measure intracellular islatravir triphosphate concentration in peripheral blood mononuclear cells and determine AUC0-168hr.

Time frame:
4, 12, 24, 96, 120, 144, and 168 hours after islatravir administration. Value at predose was inferred from plasma predose sample.
Reported as:
Geometric mean · hr*pmol/10^6 cells
Area Under the Concentration-Time Curve of Islatravir Triphosphate in Peripheral Blood Mononuclear Cells From Time 0 to 168 Hours (AUC0-168hr)
hr*pmol/10^6 cellsPanel A: 10 mg IslatravirPanel B: 2 mg IslatravirPanel C: 30 mg IslatravirPanel D: 1 mg IslatravirPanel E: 0.5 mg Islatravir
Area Under the Concentration-Time Curve of Islatravir Triphosphate in Peripheral Blood Mononuclear Cells From Time 0 to 168 Hours (AUC0-168hr)227 ± 33.346.9 ± 38.1926 ± 47.735.9 ± 27.623.1 ± 83.0
SecondaryMaximum Concentration (Cmax) of Islatravir Triphosphate in Peripheral Blood Mononuclear Cells

Blood was collected to measure intracellular islatravir triphosphate concentration in peripheral blood mononuclear cells and determine Cmax.

Time frame:
4, 12, 24, 96, 120, 144, and 168 hours after islatravir administration. Value at predose was inferred from plasma predose sample.
Reported as:
Geometric mean · pmol/10^6 cells
Maximum Concentration (Cmax) of Islatravir Triphosphate in Peripheral Blood Mononuclear Cells
pmol/10^6 cellsPanel A: 10 mg IslatravirPanel B: 2 mg IslatravirPanel C: 30 mg IslatravirPanel D: 1 mg IslatravirPanel E: 0.5 mg Islatravir
Maximum Concentration (Cmax) of Islatravir Triphosphate in Peripheral Blood Mononuclear Cells2.81 ± 49.90.495 ± 62.98.9 ± 60.30.408 ± 49.30.263 ± 54.5
SecondaryConcentration of Islatravir Triphosphate in Peripheral Blood Mononuclear Cells at 168 Hours Post-Dose (C168hr)

Blood was collected to measure intracellular islatravir triphosphate concentration in peripheral blood mononuclear cells and determine C168hr.

Time frame:
168 hours after islatravir administration
Reported as:
Geometric mean · pmol/10^6 cells
Concentration of Islatravir Triphosphate in Peripheral Blood Mononuclear Cells at 168 Hours Post-Dose (C168hr)
pmol/10^6 cellsPanel A: 10 mg IslatravirPanel B: 2 mg IslatravirPanel C: 30 mg IslatravirPanel D: 1 mg IslatravirPanel E: 0.5 mg Islatravir
Concentration of Islatravir Triphosphate in Peripheral Blood Mononuclear Cells at 168 Hours Post-Dose (C168hr)0.983 ± 260.188 ± 39.24.83 ± 85.90.164 ± 31.40.116 ± 85.6
SecondaryTime to Maximum Concentration (Tmax) of Islatravir Triphosphate in Peripheral Blood Mononuclear Cells

Blood was collected to measure intracellular islatravir triphosphate concentration in peripheral blood mononuclear cells and determine TMax.

Time frame:
4, 12, 24, 96, 120, 144, and 168 hours after islatravir administration. Value at predose was inferred from plasma predose sample.
Reported as:
Median · Hour
Time to Maximum Concentration (Tmax) of Islatravir Triphosphate in Peripheral Blood Mononuclear Cells
HourPanel A: 10 mg IslatravirPanel B: 2 mg IslatravirPanel C: 30 mg IslatravirPanel D: 1 mg IslatravirPanel E: 0.5 mg Islatravir
Time to Maximum Concentration (Tmax) of Islatravir Triphosphate in Peripheral Blood Mononuclear Cells12 (12 to 240)8 (4 to 144)24 (4 to 96)8 (4 to 24)12 (4 to 24)
SecondaryApparent Terminal Half-Life (t1/2) of Islatravir Triphosphate in Peripheral Blood Mononuclear Cells

Blood was collected to measure intracellular islatravir triphosphate concentration in peripheral blood mononuclear cells and determine apparent terminal t1/2.

Time frame:
4, 12, 24, 96, 120, 144, and 168 hours after islatravir administration. Value at predose was inferred from plasma predose sample.
Reported as:
Geometric mean · Hours
Apparent Terminal Half-Life (t1/2) of Islatravir Triphosphate in Peripheral Blood Mononuclear Cells
HoursPanel A: 10 mg IslatravirPanel B: 2 mg IslatravirPanel C: 30 mg IslatravirPanel D: 1 mg IslatravirPanel E: 0.5 mg Islatravir
Apparent Terminal Half-Life (t1/2) of Islatravir Triphosphate in Peripheral Blood Mononuclear Cells128 ± 42.2120 ± 14.778.5 ± 31.4118 ± 16.195.3 ± 38.2
SecondaryArea Under the Plasma Concentration-Time Curve of Islatravir From Time 0 to 168 Hours (AUC0-168hr)

Blood was collected for the determination of AUC0-168hr of islatravir in plasma.

Time frame:
Predose and at 0.25, 0.5, 1, 2, 4, 8, 12, 24, 48, and 96 hours after islatravir administration. Value at 168 hours was extrapolated.
Reported as:
Geometric mean · hr*nM
Area Under the Plasma Concentration-Time Curve of Islatravir From Time 0 to 168 Hours (AUC0-168hr)
hr*nMPanel A: 10 mg IslatravirPanel B: 2 mg IslatravirPanel C: 30 mg IslatravirPanel D: 1 mg IslatravirPanel E: 0.5 mg Islatravir
Area Under the Plasma Concentration-Time Curve of Islatravir From Time 0 to 168 Hours (AUC0-168hr)1020 ± 16.8143 ± 39.63020 ± 24.688.3 ± 33.838.3 ± 25.8
SecondaryMaximum Plasma Concentration (Cmax) of Islatravir

Blood was collected for the determination of Cmax of islatravir in plasma.

Time frame:
Predose and at 0.25, 0.5, 1, 2, 4, 8, 12, 24, 48, and 96 hours after islatravir administration
Reported as:
Geometric mean · nM
Maximum Plasma Concentration (Cmax) of Islatravir
nMPanel A: 10 mg IslatravirPanel B: 2 mg IslatravirPanel C: 30 mg IslatravirPanel D: 1 mg IslatravirPanel E: 0.5 mg Islatravir
Maximum Plasma Concentration (Cmax) of Islatravir235 ± 32.143.8 ± 51.2678 ± 29.638.8 ± 31.320.3 ± 36.4
SecondaryTime to Maximum Plasma Concentration (Tmax) of Islatravir

Blood was collected for the determination of Tmax of islatravir in plasma.

Time frame:
Predose and at 0.25, 0.5, 1, 2, 4, 8, 12, 24, 48, and 96 hours after islatravir administration
Reported as:
Median · Hour
Time to Maximum Plasma Concentration (Tmax) of Islatravir
HourPanel A: 10 mg IslatravirPanel B: 2 mg IslatravirPanel C: 30 mg IslatravirPanel D: 1 mg IslatravirPanel E: 0.5 mg Islatravir
Time to Maximum Plasma Concentration (Tmax) of Islatravir1 (0.5 to 1)0.5 (0.5 to 1)0.75 (0.5 to 1)0.5 (0.5 to 1)0.5 (0.25 to 0.5)
SecondaryApparent Terminal Half-Life (t1/2) of Islatravir in Plasma

Blood was collected for the determination of apparent terminal t1/2 of islatravir in plasma.

Time frame:
Predose and at 0.25, 0.5, 1, 2, 4, 8, 12, 24, 48, and 96 hours after islatravir administration
Reported as:
Geometric mean · Hours
Apparent Terminal Half-Life (t1/2) of Islatravir in Plasma
HoursPanel A: 10 mg IslatravirPanel B: 2 mg IslatravirPanel C: 30 mg IslatravirPanel D: 1 mg IslatravirPanel E: 0.5 mg Islatravir
Apparent Terminal Half-Life (t1/2) of Islatravir in Plasma59.7 ± 15.447.4 ± 74.656.8 ± 11.210.4 ± 1442.31 ± 16.7

Adverse events

Collected over Up to 21 days following administration of investigational drug. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Panel A: 10 mg Islatravir0/6 (0%)0/6 (0%)5/6 (83.3%)
Panel B: 2 mg Islatravir0/6 (0%)0/6 (0%)5/6 (83.3%)
Panel C: 30 mg Islatravir0/6 (0%)0/6 (0%)6/6 (100%)
Panel D: 1 mg Islatravir0/6 (0%)0/6 (0%)5/6 (83.3%)
Panel E: 0.5 mg Islatravir0/6 (0%)0/6 (0%)6/6 (100%)
Most frequent other events
Showing 10 of 30
Most frequent other events
EventPanel A: 10 mg IslatravirPanel B: 2 mg IslatravirPanel C: 30 mg IslatravirPanel D: 1 mg IslatravirPanel E: 0.5 mg Islatravir
HeadacheNervous system disorders5/61/60/62/62/6
Viral upper respiratory tract infectionInfections and infestations0/60/63/61/60/6
DiarrhoeaGastrointestinal disorders1/62/61/61/61/6
VomitingGastrointestinal disorders0/60/61/62/60/6
HyperhidrosisSkin and subcutaneous tissue disorders0/61/60/62/60/6
Angina pectorisCardiac disorders0/61/60/60/60/6
Abdominal painGastrointestinal disorders0/60/61/60/60/6
Abdominal pain upperGastrointestinal disorders1/60/60/60/61/6
NauseaGastrointestinal disorders1/60/60/61/60/6
Oral mucosa erosionGastrointestinal disorders0/61/60/60/60/6

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Panel A: 10 mg IslatravirPanel B: 2 mg IslatravirPanel C: 30 mg IslatravirPanel D: 1 mg IslatravirPanel E: 0.5 mg IslatravirTotal
Mean31.5 ± 10.042.2 ± 9.835.5 ± 9.132.7 ± 12.735.5 ± 11.335.5 ± 10.6
Sex: Female, Male
Sex: Female, Male(Participants)Panel A: 10 mg IslatravirPanel B: 2 mg IslatravirPanel C: 30 mg IslatravirPanel D: 1 mg IslatravirPanel E: 0.5 mg IslatravirTotal
Female000000
Male6666630
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Panel A: 10 mg IslatravirPanel B: 2 mg IslatravirPanel C: 30 mg IslatravirPanel D: 1 mg IslatravirPanel E: 0.5 mg IslatravirTotal
Hispanic or Latino200103
Not Hispanic or Latino4665627
Unknown or Not Reported000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Panel A: 10 mg IslatravirPanel B: 2 mg IslatravirPanel C: 30 mg IslatravirPanel D: 1 mg IslatravirPanel E: 0.5 mg IslatravirTotal
American Indian or Alaska Native000000
Asian000101
Native Hawaiian or Other Pacific Islander000000
Black or African American000000
White6665629
More than one race000000
Unknown or Not Reported000000
Plasma HIV-1 Ribonucleic Acid (RNA)
Plasma HIV-1 Ribonucleic Acid (RNA)(log10 copies/mL)Panel A: 10 mg IslatravirPanel B: 2 mg IslatravirPanel C: 30 mg IslatravirPanel D: 1 mg IslatravirPanel E: 0.5 mg IslatravirTotal
Mean4.68 ± 0.394.7 ± 0.254.17 ± 0.414.66 ± 0.24.59 ± 0.54.56 ± 0.40
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Schurmann D, Rudd DJ, Zhang S, De Lepeleire I, Robberechts M, Friedman E, Keicher C, Huser A, Hofmann J, Grobler JA, Stoch SA, Iwamoto M, Matthews RP. Safety, pharmacokinetics, and antiretroviral activity of islatravir (ISL, MK-8591), a novel nucleoside reverse transcriptase translocation inhibitor, following single-dose administration to treatment-naive adults infected with HIV-1: an open-label, phase 1b, consecutive-panel trial. Lancet HIV. 2020 Mar;7(3):e164-e172. doi: 10.1016/S2352-3018(19)30372-8. Epub 2020 Jan 3. PubMed 31911147 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2015 to primary completion in May 2017, 19 months.

Results were first posted in Dec 2018, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2014
First posted
Aug 15, 2014
StartActual
Sep 17, 2015
Primary completionActual
May 11, 2017
CompletionActual
May 11, 2017
Results first posted
Dec 3, 2018
Last update
Aug 12, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02217904
Responsible party
Sponsor
First posted
Aug 15, 2014
Start date
Sep 17, 2015
Primary completion
May 11, 2017
Completion
May 11, 2017
Results posted
Dec 3, 2018
Last update
Aug 12, 2019

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Islatravir

Start the discussion